Show simple item record

dc.creatorAbdool Karim, Quarraisha.
dc.creatorBaxter, Cheryl.
dc.creatorAbdool Karim, Salim Safurdeen.
dc.date.accessioned2013-12-11T09:00:01Z
dc.date.available2013-12-11T09:00:01Z
dc.date.created2013
dc.date.issued2013
dc.identifier.citationAbdool Karim, Q., Baxter, C., & S.S. Abdool Karim. 2013. Topical Microbicides - What's new? Journal of Acquired Immune Deficiency Syndrome 63 Supplement 2 pp. S144–S149.
dc.identifier.issn1525-4135
dc.identifier.urihttp://dx.doi.org/10.1097/QAI.0b013e3182986f80en
dc.identifier.urihttp://hdl.handle.net/10413/10200
dc.description.abstractTopical microbicides are an important, promising but complex HIV prevention technology under development. After 11 disappointing effectiveness trial outcomes of 6 candidate products (some tested as multiple doses and formulations) over the past 20 years, there is renewed optimism that a safe and effective microbicide will soon be available if the recent success of coitally linked use of the antiretroviral-based microbicide, 1% tenofovir gel, is confirmed. Studies of new antiviral agents, novel delivery mechanisms, and combination/multipurpose products that address challenges of adherence, enhance the effectiveness of tenofovir gel, and address sexual and reproductive health needs of men and women, including preventing HIV infection, are already underway.en
dc.language.isoenen
dc.publisherLippincott Williams & Wilkins.en
dc.subjectHIV infections--Prevention.en
dc.subjectAntiretroviral agents.en
dc.subjectAIDS vaccines.en
dc.subject.otherAntiretroviral microbicides.en
dc.subject.otherAntiretroviral microbicides trials.en
dc.subject.otherTenofovir gel.en
dc.subject.otherTopical microbicides.en
dc.titleTopical microbicides - What's new?en
dc.typePeer reviewed journal articleen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record